Cellar boy (@boy_cellar) header
Cellar boy (@boy_cellar) profile picture

Derivatives trader. AIM investing with a focus on Biotech.

Joined November 2020
Photo by Cellar boy (@boy_cellar)Photo by Cellar boy (@boy_cellar)Photo by Cellar boy (@boy_cellar)Photo by Cellar boy (@boy_cellar)Photo by Cellar boy (@boy_cellar)Photo by Cellar boy (@boy_cellar)Photo by Cellar boy (@boy_cellar)Photo by Cellar boy (@boy_cellar)Photo by Cellar boy (@boy_cellar)Photo by Cellar boy (@boy_cellar)
Cellar boy retweeted
Replying to @boy_cellar
I believe they are attending AACR.
3
1
6
919
Cellar boy retweeted
The week before last folk were spreading baseless rumours about #AVCT’s Dx sale having fallen through. On Friday AVCT confirmed Launch had been sold and the current cash balance is enough to see the company into Q1 2026. Coris is yet to be sold but if you assume the same haircut, you can assume c.£17m total sale price for both Dx units. The amount we receive for Coris will be = to approx x1 CLN payment. A few weeks before, folk were spreading rumours P1b had been delayed. On Friday, AVCT confirmed P1b is well underway. WithPower tracks the number of available spots accurately: ~34 remain. This is of a potential 60-90 total (AVCT confirmed on Friday there will be 20-30 patients per P1b cohort). Therefore, the worst case as of Friday is 26 patients already enrolled (60-34). The best case is 56 patients have been enrolled (90-34). Either figure is a step change in speed. P1b does not follow a 3+3 design so we don’t have to wait to see if a dose is safe before escalating as we did in P1a. We are still in the dark on trial design (for good reason) but dosing may be bi-weekly in P1b (which seems likely given the highly favourable PK from Q2W dosing), but it could also be Q3W for certain indications. Consider AVCT has been in P1b for a number of weeks now (we don’t know exactly how long). Then consider the heavily pre-treated SGC patient was seeing complete regression of metastasis after just two cycles (6 weeks). When AVA6000 works, it works quickly. And when they stop dosing AVA6000 it continues to work. This takes us to the PFS figures - also released on Friday - which confirm of the 11 SGC patients, 9 are without disease progression. The median time of follow up is approx 5 months. The literature in this *pre-treated* SGC setting reports a PFS of approximately 3.5 months. As @Blueberrymgmnt states, Dox is not the standard of care for SGC. It’s often a combo. What’s more, recognise just how heavily pre-treated these SGC patients were in P1a. In P1b it’s a different make-up. With 0 or 1 prior line of therapy permitted. Median PFS is not the median of the time of disease progression or death but the time when 50% or more patients have progressed disease or have died. I.e. AVCT has already beaten the PFS (which will likely be the endpoint they use in the registrational trial of AVA6000). To reach the median PFS AVCT will need to see 4 of remaining patients see their disease progress. What is unique about AVA6000 is with naked dox you would typically expect those patients who have had to stop treatment (due to safety) see their cancer grow. What is happening with AVA6000 is even after dosing has stopped, the cancer is kept at bay. Why? The bystander effect is the process whereby cancer cells that have received a specific therapy are able to bring about growth inhibition in untreated cells in the same tumour population. pre|CISION leverages the bystander effect to efficiently kill both FAP+ and FAP-cells. So even after the drug has stopped being dosed, it is keeping the cancer at bay. We saw this with the patient who saw complete regression of his skin metastases. Three others are experiencing this bystander effect, too. Note this patient was enrolled in September 2024. 6+ months ago. He had four cycles of 385mg every 3 weeks. So he stopped dosing sometime in December. Despite stopping dosing, he was continuing to see his lesions shrink. At the time of the RNS last week (ie early March) he has still not seen disease progression, despite stopping the drug c. 3 months ago. Hopefully he does not see progression (but if he were to) he would need to be joined by another 3 patients (who have also seen disease progression) for AVCT to hit their median PFS. Or by some of the other 5 patients who remain on drug. As a result, AVCT are now signalling a readout in Q2 2025. That is surely so they can update on the median PFS on the SGC cohort SGC will soon have a standard of care. Some see that, some don’t.
3
18
113
7,448
Cellar boy retweeted
#AVCT volume remains suggestive something is afoot: (1) II building a stake unbeknown to mgmt; (2) Pharma/II building a stake, known to mgmt; (3) Peel have done what STFL failed and found safe harbour for CLN stock. Whatever is driving it, it’s significant in size and can’t remain unknown for much longer. It’s simply too large and too repetitive for there to be nothing behind it. @avacta will present c.27 months of PK data at the end of Nov/beginning of Dec. A seminal moment for the platform of a young biotech which is now able to dose a drug that can prove fatal on a single dose at these levels, safely. I’m expecting AVCT to run up into the PK release given the only thing holding the stock back was the perception of Heights. Literally the only thing. Exploited of course by everyone who wanted a lower position or traded it on a quarterly basis. There was even a group set up by shareholders to trade the stock and contribute to this volatility (well done you, by the way). Nobody on here shorted it, despite what they say. They didn’t have the platform nor the means. Those who did have the ability, aren’t the types you want to follow into trades: JUP - whose market cap I believe we will exceed this week. Bronte - who can’t beat the benchmark, ever. The old volume enabled this tired rhetoric. The new volume renders it redundant. AVCT is seeing significant tumour reduction in STS and other patients who were not anticipated to respond, remain on drug. They are seeing none of the key toxicities in any patients. A 7% return over 2+ years is an absurd reward for a solution to a 50 yr old problem. Especially when Pharma is on a buying spree. PK data fires that gun. FortySeven is a perfect example of what data publication can lead to: Oct 2019 - $6 Nov 2019 - P1b data showed FortySeven had gone *part way* to proving IP. Mar 2020 - sold for $95 ($4.9Bn) 5 month move: $6>$95 AVCT has a plethora of options. A CEO almost cocky in his funding situation (‘don’t worry about it’) and a world-beating platform. Which “works”. We’re 20-25 sessions from seeing exactly that feeds the CEO’s confidence. I suspect it’s much better than even the optimists hope for. Then, as you can see from Myles’s note below, you have the vast versatility of the platform laid bare. All for 7% over 2+ years. So go on, short it on your mythical platform.
7
19
2
128
11,647
Replying to @avacta
@Avacta are revolutionising the treatment of #cancer with its targeted #chemotherapy with its second pre|CISION TM drug #AVA3996 in pre-clinical research. #AVCT #MelanomaMonday #MelanomaAwarenessMonth23 #melanoma @CureMelanoma
1
29
2
73
9,000
Gary Lineker suspended by the BBC for upsetting the Conservatives because he stood up for some of the most vulnerable people in the world. The same BBC whose chairman gave the Conservatives £400,000 before helping to arrange an £800,000 loan for Boris Johnson
2,313
20,566
3,709
78,959
10,419,537
Cellar boy retweeted
You can borrow someone else’s stock ideas but you can’t borrow their conviction.
12
34
6
319
54,092
Agreed, it feels like an impending commercial announcement to go with the trial data. Booking the science day could be a bargaining tool to get better terms. “We’re prepared to fund it ourselves…”
1
2
24
1,596
Cellar boy retweeted
If you can hold your nose through the LFT chatter, the original @InvestorMeetCo audio from Dr MJ worth a listen. I hadn’t appreciated P1a would def include: STS; Breast; Ovarian. “you know early if it’s not going to plan”. 420+ days later the lead investigator turns up at HQ.
1
2
22
Cellar boy retweeted
10x more people will want to buy a stock after it doubles. 1/4 as many people will want to buy a stock after it gets cut in half. It's just how it works.
24
47
5
580
Cellar boy retweeted
The prime minister refuses to say what ‘local consent’ for fracking would look like, amid some long pauses. “It sounds like you don’t know.”
50
176
156
743
Liz Truss has spoken today to Ukraine's president about the ongoing crisis Zelensky promised to provide all the assistance he could
433
8,328
598
70,602
Cellar boy retweeted
Booking that came down today? #WhereisthePM
71
229
55
2,689
Mortgage lenders are pulling deals because the cost of borrowing over 2 or 5 years has shot up so fast along with gilt yields. That’s happening regardless of attempts at calming by BoE. I can’t remember seeing that before - and I’ve been reporting financial markets for 27 years.
108
1,636
112
4,976
Cellar boy retweeted
Made this one for you @mrjamesob
330
6,752
540
31,182
Cellar boy retweeted
Just talking to @IainDale at #Lab22 and a Labour member interrupts to thank him for his support with the strikes. She thought he was Mick Lynch…
147
247
54
3,094
We keep having to rewrite the top of the splash because financial markets do not want to touch sterling
158
1,236
184
3,836
Another drug in development, AVA6000, has been given Orphan Drug designation by the FDA, for soft tissue sarcomas. This is a pro-drug version of doxorubicin which is intended to target the tumor and minimize side effects to normal tissues. tinyurl.com/doxorubicin #sarcoma
4
1
20
my portfolio every time it goes up a bit nitter.gq/videosvecagando/status…
7
35
6
329
Replying to @AdamBienkov
My local A&E last night.
848
3,241
1,789
8,844
It's not running late. How big is the interest and how much would onlookers like to cement that interest to be first to the punch. Wheels could already be in motion for all we know. There is a deafening silence and people should be prepared. "Soon"
2
10